WCLC 2025 - Posters & ePosters-PT2.17.03 Accelerated Biological Aging Is Correlated With the Incidence and Poor Prognosis of Young Lung Cancer

Pdf Summary

This multicenter case-control study, supplemented by UK Biobank validation, investigated the association between accelerated biological ageing—measured by PhenoAge acceleration (PhenoAgeAccel)—and early-onset lung cancer (ages 40–50), focusing on risk and prognosis. PhenoAgeAccel quantifies biological age relative to chronological age, with positive values indicating accelerated ageing.<br /><br />Key findings reveal that younger lung cancer patients exhibit significantly higher PhenoAgeAccel compared to healthy controls, indicating pronounced biological ageing. Increased PhenoAgeAccel was linked to an 18% higher lung cancer risk per standard deviation increase among younger adults, with strong discriminatory ability (AUC=0.752). In contrast, older patients (≥65 years) showed no significant difference in PhenoAgeAccel or predictive capacity, highlighting a specific impact in early-onset cases.<br /><br />Moreover, patients with lower PhenoAgeAccel demonstrated substantially better overall survival (OS), with high acceleration corresponding to over twice the mortality risk (HR=2.17). UK Biobank data corroborated these findings, showing a rightward shift in PhenoAgeAccel in patients versus controls and confirming poorer long-term survival with higher PhenoAgeAccel (HR=1.65). Inflammatory and metabolic biomarkers underlying PhenoAge contribute to lung cancer development but should be interpreted within holistic biological ageing rather than isolated factors.<br /><br />Overall, accelerated biological ageing emerges as a crucial factor influencing both susceptibility and prognosis in early-onset lung cancer. PhenoAgeAccel may serve as a valuable biomarker for early detection, risk stratification, and potentially personalized therapeutic strategies in younger patients. These results underscore the clinical importance of including biological ageing metrics in guiding screening and management tailored to this vulnerable population.

Asset Subtitle

Yuxuan Liao

Meta Tag

Speaker Yuxuan Liao

Topic Global Health, Health Services, and Health Economics

Keywords

accelerated biological ageing

PhenoAge acceleration

early-onset lung cancer

lung cancer risk

prognosis

UK Biobank validation

biological age vs chronological age

overall survival

biomarkers

risk stratification